OOIR: Observatory of International Research

Papers

(The H4-Index of ACS Medicinal Chemistry Letters is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring	143
Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport	138
Issue Editorial Masthead	132
Issue Publication Information	83
Issue Publication Information	69
Macrocyclic Oxindole Peptide Epoxyketones─A Comparative Study of Macrocyclic Inhibitors of the 20S Proteasome	63
Cancer-Cell-Selective Targeting by Arylcyclopropylamine–Vorinostat Conjugates	58
Clozapine as an E3 Ligand for PROTAC Technology	50
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential	49
Polybromo-1 Bromodomain Inhibitor Selectivity Is Mediated by a Unique Ligand-Binding Pocket	47
Design and Synthesis of a Structurally Stabilized B-Chain Antagonist Targeting Relaxin Family Peptide Receptor 3 (RXFP3)	46
Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine	46
Virtual Screening-Guided Discovery of Small-Molecule CHI3L1 Inhibitors with Functional Activity in Glioblastoma Spheroids	44
Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer	42
Novel Heterocyclic Pyrimidine Derivatives as GSK3α Inhibitors	40
Novel Tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepine Compounds as Oxytocin Receptor Agonists for Treating Autism Spectrum Disorders	40
In This Issue, Volume 14, Issue 5	37
Call for Papers: Fungal Pathogens – Life Cycle, Infection, Host Immunity and Drug Discovery	36
Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1–Nrf2 PPI Inhibitor	35
Discovery of Selective Inhibitors of Na_V1.7 Templated on Saxitoxin as Therapeutics for Pain	35
Novel Phosphorylpurinone Compounds for Treating Cancer	35
Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes	34
Design and Characterization of 1,3-Dihydro-2H-benzo[d]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors	34
Discovery of Pyridopyrazine Inverse Agonists Targeting G Protein-Coupled Receptor 6	33
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics	32

Discovery of Niclosamide Analogs with Potent Mitochondrial Uncoupling Activity and Reduced Mitochondrial Inhibition–Associated Toxicity	32
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach	31
Structure–Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2	31
Discovery of a Novel sp³-Rich M₁ Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping	31
Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation	31
Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan	31
Application of Deuterated N,N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders	31